Game Of Thrones: Bayer Looks To Lead China’s OTC Market

The recent acquisition of Dihon Pharmaceutical Group marks progress toward Bayer’s goal of becoming the leader in the OTC sector in China. Dihon provides an entry into the TCM arena, which makes up about half of the OTC segment in China, the firm says.